CLAIMS

1. A pharmaceutical composition comprising capivasertib or a pharmaceutically acceptable salt thereof, microcrystalline cellulose and dicalcium phosphate anhydrous, where the pharmaceutical composition comprises 40%-50% w/w of capivasertib or a pharmaceutically acceptable salt thereof, the combined amount of microcrystalline cellulose and dicalcium phosphate anhydrous in the pharmaceutical composition is from 40% w/w to 60% w/w, and the ratio of microcrystalline cellulose to dicalcium phosphate anhydrous is from 45:55 to 70:30.

2. A pharmaceutical composition as claimed in claim 1, which is an immediate release pharmaceutical composition.

3. A pharmaceutical composition as claimed in claim 1 or claim 2, where the pharmaceutical composition comprises about 40% w/w of capivasertib or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition as claimed in any of the preceding claims, where the ratio of microcrystalline cellulose to dicalcium phosphate anhydrous is from 55:45 to 68:32, such as about 6:4.

5. A pharmaceutical composition as claimed in any of the preceding claims, where the combined amount of microcrystalline cellulose and dicalcium phosphate anhydrous is from 50% w/w to 55% w/w.

6. A pharmaceutical composition as claimed in any of the preceding claims, further comprising at least one disintegrant in an amount of up to 10% w/w, such as up to 5% w/w, and optionally where the at least one disintegrant is croscarmellose sodium.

7. A pharmaceutical composition as claimed in any of the preceding claims, further comprising at least one lubricant in an amount of up to 4% w/w, such as up to 1.5% w/w, and optionally where the at least one lubricant is magnesium stearate.

8. A pharmaceutical composition as claimed in claim 1, comprising:
   - About 40% w/w capivasertib;

- microcrystalline cellulose and dicalcium phosphate anhydrous, where the ratio of microcrystalline cellulose to dicalcium phosphate anhydrous is about 6:4, and the combined amount of microcrystalline cellulose and dicalcium phosphate anhydrous is 50%-55% w/w;
- Croscarmellose sodium in an amount of about 5% w/w; and
- Magnesium stearate in an amount of about 1.5% w/w.

9. An oral solid dosage form comprising a pharmaceutical composition as claimed in any of claims 1 to 8, where the oral solid dosage form is a tablet.

10. An oral solid dosage form as claimed in claim 9, where the oral solid dosage form is a tablet comprising a core comprising a pharmaceutical composition as claimed in any of claims 1 to 8, and a coating over the core.

11. An oral solid dosage form as claimed in claim 10, wherein the core comprises:
- About 40% w/w capivasertib;
- microcrystalline cellulose and dicalcium phosphate anhydrous, where the ratio of microcrystalline cellulose to dicalcium phosphate anhydrous is about 6:4, and the combined amount of microcrystalline cellulose and dicalcium phosphate anhydrous is 50%-55% w/w;
- Croscarmellose sodium in an amount of about 5% w/w; and
- Magnesium stearate in an amount of about 1.5% w/w.

12. An oral solid dosage form as claimed in claim 10 or claim 11, where the coating comprises hypromellose 2910, copovidone plasdone S630, polyethylene glycol 3350, polydextrose, at least one caprylic/capric triglyceride, titanium dioxide, iron oxide yellow, iron oxide red and iron oxide black.

13. An oral solid dosage form as claimed in any of claims 9 to 12, containing 80 mg, 160 mg or 200 mg of capivasertib.

14. An oral solid dosage form as claimed in any of claims 9 to 13, comprising:
- 200 mg capivasertib;
- 160.5 mg microcrystalline cellulose;
- 107.0 mg dicalcium phosphate anhydrous;
- 25.0 mg croscarmellose sodium; and
- 7.5 mg magnesium stearate.

15. An oral solid dosage form as claimed in any of claims 9 to 13, comprising:

- 160 mg capivasertib;
- 128.4 mg microcrystalline cellulose;
- 85.6 mg dicalcium phosphate anhydrous;
- 20 mg croscarmellose sodium; and
- 6 mg magnesium stearate.

16. A process for manufacturing an oral solid dosage form as claimed in any of claims 9 to 15, comprising the steps of:

i) Blending a mixture comprising capivasertib or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, and dicalcium phosphate anhydrous and optionally a disintegrant and/or a lubricant to form a blend;

ii) Dry granulating the blend; and

iii) Compressing the dry granulated blend into a tablet;

optionally wherein the dry granulation process in step ii) is performed by roller compaction of the blend followed by milling.

17. Use of a pharmaceutical composition as claimed in any of claims 1 to 8, or an oral solid dosage form as claimed in any of claims 9 to 15, in the manufacture of a medicament for the treatment of cancer.

18. A pharmaceutical composition as claimed in any of claims 1 to 8, or an oral solid dosage form as claimed in any of claims 9 to 15 for use in therapy.